

# Rony Dahan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6424958/publications.pdf>

Version: 2024-02-01

24  
papers

2,427  
citations

471509

17  
h-index

610901

24  
g-index

27  
all docs

27  
docs citations

27  
times ranked

5034  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. <i>Nature Cancer</i> , 2022, 3, 287-302.	13.2	29
2	Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. <i>Science Advances</i> , 2022, 8, eabm4552.	10.3	5
3	Artificial Antigen Presenting Cells for Detection and Desensitization of Autoreactive T cells Associated with Type 1 Diabetes. <i>Nano Letters</i> , 2022, 22, 4376-4382.	9.1	3
4	Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis. <i>Nature Communications</i> , 2021, 12, 602.	12.8	48
5	Unified platform for genetic and serological detection of COVID-19 with single-molecule technology. <i>PLoS ONE</i> , 2021, 16, e0255096.	2.5	5
6	Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. <i>Cell Reports</i> , 2021, 37, 110114.	6.4	44
7	Single-cell genomic approaches for developing the next generation of immunotherapies. <i>Nature Medicine</i> , 2020, 26, 171-177.	30.7	84
8	BCR affinity differentially regulates colonization of the subepithelial dome and infiltration into germinal centers within Peyer's patches. <i>Nature Immunology</i> , 2019, 20, 482-492.	14.5	39
9	Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 11048-11053.	7.1	66
10	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. <i>Immunity</i> , 2017, 46, 577-586.	14.3	323
11	Signaling by Antibodies: Recent Progress. <i>Annual Review of Immunology</i> , 2017, 35, 285-311.	21.8	167
12	Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. <i>Cell Reports</i> , 2016, 15, 2000-2011.	6.4	452
13	Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement. <i>Cancer Cell</i> , 2016, 30, 369-371.	16.8	6
14	Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. <i>Cancer Cell</i> , 2016, 29, 820-831.	16.8	135
15	FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. <i>Cancer Cell</i> , 2015, 28, 285-295.	16.8	291
16	Type I and type II Fc receptors regulate innate and adaptive immunity. <i>Nature Immunology</i> , 2014, 15, 707-716.	14.5	425
17	HLA-DRβ1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2014, 192, 4164-4173.	0.8	48
18	Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associated auto-reactive T cell epitope. <i>Journal of Autoimmunity</i> , 2013, 47, 83-93.	6.5	14

#	ARTICLE	IF	CITATIONS
19	A novel regulatory pathway for autoimmune disease: Binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. <i>Journal of Autoimmunity</i> , 2013, 40, 96-110.	6.5	41
20	T-cell-receptor-like antibodies – generation, function and applications. <i>Expert Reviews in Molecular Medicine</i> , 2012, 14, e6.	3.9	69
21	TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes. <i>European Journal of Immunology</i> , 2011, 41, 1465-1479.	2.9	12
22	A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS. <i>Journal of Neuroscience</i> , 2007, 27, 12531-12539.	3.6	50
23	HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes. <i>Journal of Neuroscience Research</i> , 2004, 78, 100-114.	2.9	15
24	Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	8